ASTX029 / Otsuka  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ASTX029 / Otsuka
NCT03520075 / 2018-004568-72: Study of ASTX029 in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
300
Europe, US
ASTX029
Astex Pharmaceuticals, Inc.
Solid Tumor, Adult
04/24
12/25
NCT06284460: Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Not yet recruiting
1/2
36
US
ASTX029, ASTX727, Inqovi
M.D. Anderson Cancer Center
Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm, Myeloproliferative Neoplasm
12/25
12/27
NCT06113289: A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia

Suspended
1/2
42
US
ASTX727, Inqovi, ASTX029-01
M.D. Anderson Cancer Center
Acute Myeloid Leukemia
05/27
05/29

Download Options